Timing of Anticoagulation Resumption and Risk of Ischemic and Hemorrhagic Complications in Patients with Intracranial Hemorrhage and Mechanical Heart Valves

Neurology Hematology Neurosurgery Medicine Cardiovascular System
Anticoagulation Ischemic Complications Hemorrhagic Complications Mechanical Heart Valves Intracranial Hemorrhage

Exploration of Anticoagulation Therapy Resumption Time After ICH in Mechanical Heart Valve Patients

Background and Motivation

For patients with mechanical heart valves, determining the appropriate time to resume oral anticoagulation therapy after experiencing an intracerebral hemorrhage (ICH) remains a significant clinical challenge. These patients require anticoagulation therapy to prevent thromboembolic events, but such treatment can also lead to the expansion of intracerebral hematomas. Balancing the risk of thromboembolism during the anticoagulation pause with the risk of ICH expansion upon resuming anticoagulation therapy is a persistent dilemma for clinicians. Current international guidelines recommend resuming anticoagulation therapy but do not provide specific timing recommendations. This is due to the lack of randomized controlled trials (RCTs) to determine the optimal resumption time for anticoagulation therapy in mechanical heart valve patients after ICH. Existing retrospective observational studies have been limited by sample sizes and inconsistent results, further complicating this issue.

Source and Author Information

This paper is authored by Amra Sakusic, Alejandro A. Rabinstein, Bhrugun Anisetti, Jay Mandrekar, Eelco F.M. Wijdicks, William D. Freeman, and Sherri A. Braksick. They are affiliated with various neurology and biostatistics departments at the Mayo Clinic. The paper was published in the August 27, 2024, volume 4 issue of the journal Neurology.

Study Design and Process

The study is designed as a retrospective cohort observational study, including all eligible adult patients with mechanical heart valves treated at the Mayo Clinic from January 1, 2000, to July 13, 2022. The study subjects were patients hospitalized for acute intracerebral hemorrhage, identified using electronic search algorithms with International Classification of Diseases (ICD) codes and text searches related to mechanical heart valves. Inclusion criteria were patients with mechanical valves and ICH, while patients with conditions such as cerebral amyloid angiopathy (CAA) or high rebleeding risk were excluded.

To ensure the validity of the study, the research team manually reviewed the electronic medical records of all patients, collecting data from the initial ICH event until July 13, 2022, or the patient’s death.

Study Subjects and Analysis Methods

A total of 171 patients with mechanical heart valves and ICH were included in the analysis. The median age of the study subjects was 75 years, with 68.4% being male. Most patients (79.5%) received anticoagulation reversal treatment, mainly including prothrombin complex concentrate (PCC), vitamin K, fresh frozen plasma (FFP), or a combination thereof. Post-surgery, 11 patients experienced ischemic stroke during the anticoagulation pause (6.4%), while 17 patients had ICH expansion after resuming anticoagulation therapy (9.9%).

Data analysis was performed using SAS software. Descriptive statistics for all continuous variables were presented as medians and interquartile ranges (IQR), and categorical variables were expressed as frequencies and percentages. Correlation tests were conducted using the χ2 test or Fisher’s exact test, and comparisons of continuous variables were made using the Wilcoxon rank-sum test. A p-value of less than 0.05 was considered statistically significant.

Findings and Results

  1. Relationship between Anticoagulation Reversal Treatment and Thromboembolic Events: The study found that patients who received anticoagulation reversal treatment did not have a significantly increased risk of thromboembolic events. Patients treated with PCC and FFP had similar risks of ischemic complications.

  2. Relationship between Anticoagulation Resumption Time and Thromboembolic Events: The ischemic stroke rate during the anticoagulation pause was low (5.3%), with most strokes occurring after a pause of more than seven days, suggesting that pausing anticoagulation for more than seven days may be safe.

  3. Relationship between Anticoagulation Resumption Time and ICH Expansion Risk: Approximately 10% of patients experienced ICH expansion after resuming anticoagulation therapy. The risk of ICH expansion was not related to the timing of anticoagulation resumption but was significantly associated with intravenous bridging therapy.

  4. Patient Outcomes: Notably, patients who experienced ICH expansion had a significantly higher mortality rate compared to those who had ischemic events during the anticoagulation pause (41% vs. 9%).

Conclusions

This study is the first to emphasize that the use of anticoagulation reversal in mechanical heart valve patients after ICH is safe, providing new insights into balancing the risks of ischemia and hemorrhage. The study results suggest that pausing anticoagulation for seven days after the initial ICH is safe, and earlier resumption should only be considered in patients with other major thromboembolic risk factors. Additionally, the study strongly recommends avoiding intravenous bridging anticoagulation when resuming anticoagulation therapy.

Highlights

  1. Large Sample Size and Long-term Follow-up: The study covers 171 patients over nearly 22 years, providing broadly representative data.
  2. New Insights: Indicates that delaying anticoagulation therapy resumption for seven days is safe in patients with mechanical heart valves.
  3. Clinical Significance: Supports avoiding intravenous bridging anticoagulation when resuming anticoagulation therapy.

Limitations

Despite the large scale and long-term follow-up, this is a retrospective observational study relying on existing data rather than a predetermined sample size. Additionally, clinical decisions made by doctors could introduce treatment indication bias. Future large multicenter cohort studies are necessary to verify these conclusions.

Clinical and Scientific Value

This study has significant clinical implications, particularly in managing ICH in patients with mechanical heart valves. By providing safer anticoagulation therapy resumption timing, the study results help optimize treatment strategies, reducing the risks of bleeding and thromboembolism. Future research can further explore the optimal timing for stopping and resuming anticoagulation therapy and ways to minimize related complications.